2.65
-0.04 (-1.49%)
| Penutupan Terdahulu | 2.69 |
| Buka | 2.63 |
| Jumlah Dagangan | 618,882 |
| Purata Dagangan (3B) | 303,278 |
| Modal Pasaran | 71,471,032 |
| Harga / Buku (P/B) | 0.360 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -2.50 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 11.19% |
| Nisbah Semasa (MRQ) | 16.92 |
| Aliran Tunai Operasi (OCF TTM) | -47.42 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -32.29 M |
| Pulangan Atas Aset (ROA TTM) | -32.46% |
| Pulangan Atas Ekuiti (ROE TTM) | -55.19% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Alto Neuroscience, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | -0.67 |
|
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 7.48% |
| % Dimiliki oleh Institusi | 89.38% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Alpha Wave Global, Lp | 31 Dec 2024 | 3,707,757 |
| Vestal Point Capital, Lp | 31 Dec 2024 | 915,000 |
| 72 Investment Holdings, Llc | 31 Dec 2024 | 667,778 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 20 Mar 2025 | Pengumuman | Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights |
| 13 Mar 2025 | Pengumuman | Christopher Nixon Cox Named Chairman of High-Trend International Group |
| 25 Feb 2025 | Pengumuman | Alto Neuroscience to Participate in Upcoming Investor Conferences |
| 19 Feb 2025 | Pengumuman | Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker |
| 12 Feb 2025 | Pengumuman | Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |